2Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond[J]. Nat Rev Cancer, 2003, 3(12): 912- 920.
3Chung CH, Bernard PS, Perou CM, et al. Molecular portraits and the family tree of cancer [J]. Nat Genet, 2002, 32 (Suppl) : 533- 540.
4Michor F, Iwasa Y, Nowak MA. Dynamics of cancer progression [J]. Nat Rev Cancer, 2004,4(3) 197-205.
5Simon R, Nocito A, Hubscher T, amplification and overexpresslon J Natl Cancer et al. Patterns of her-2/neu in primary and metastatic Inst, 2001,93(15): 1141-1146.
6Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management [J]. Oncologist, 2008,13(8) 838-844.
7Hermeking H. The MYC oncogene as a cancer drug target [J]. Curr Cancer Drug Targets, 2003,3(3):163-175.
8Dawood S, Resetkova E, Gonzalez-Angulo AM. Trastuzumab administration associated with change in HER2 status[J]. Clin Breast Cancer, 2008,8(4):366- 369.
9Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma [J]. Cancer, 2005,103 (9) : 1763-1769.
10Neubauer H, Gall C, Vogel U,et al. Changes in tumour biological markers during primary systemic chemotherapy (PST) [J]. Amicancer Res, 2008,28(3B):1797-1804.
